Figures computed from official regulatory filings — .
Analysttarget 66.71 USD (+13%) · consensus 3.54/5 · 10 buy · 17 hold · 1 sell
Ownershipinsiders 0.1% · institutions 84.85% · short 2.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BRISTOL MYERS SQUIBB CO only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
45 buys405 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Gallman Cari | Other | $142.6K | Unusual size | SEC |
| Gallman Cari | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gallman Cari | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rice Derica W | AwardD (derivative) | $38.8K | SEC |
| McMullen Michael R. | AwardD (derivative) | $35K | SEC |
| Samuels Theodore R. IItrack record | AwardD (derivative) | $51.2K | SEC |
| YALE PHYLLIS R | AwardD (derivative) | $35K | SEC |
| Arduini Peter J | AwardD (derivative) | $35K | SEC |
| Massacesi Cristian | Sell | $403.5K | SEC |
| Short Bartie Wendy | Exercise | $82.7K | SEC |
| Short Bartie Wendy | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Short Bartie Wendy | Other | $42.4K | SEC |
| Holzer Phil M | Sell | $33.8K | SEC |
| Gallman Cari | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gallman Cari | Other | $35.5K | SEC |
| Massacesi Cristian | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gallman Cari | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Massacesi Cristian | Other | $1.7M | SEC |
| Massacesi Cristian | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McMullen Michael R. | AwardD (derivative) | $35K | SEC |
| YALE PHYLLIS R | AwardD (derivative) | $35K | SEC |
| Rice Derica W | AwardD (derivative) | $38.8K | SEC |
| Samuels Theodore R. IItrack record | AwardD (derivative) | $51.2K | SEC |
| Arduini Peter J | AwardD (derivative) | $35K | SEC |
| Haller Julia A | Exercise | $1.1M | SEC |